HOTH - Hoth Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
4.8000
-0.1900 (-3.81%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close4.9900
Open5.1200
Bid4.2500 x 800
Ask5.1200 x 1000
Day's Range4.6300 - 5.1200
52 Week Range3.2600 - 13.8800
Volume16,367
Avg. Volume49,206
Market Cap48.572M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.5540
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est10.00
  • Hoth Therapeutics Announces Positive Preliminary, Preclinical Data on its Therapeutic for Cutaneous Lupus Erythematosus (CLE), a Chronic Autoimmune Skin Disease
    PR Newswire

    Hoth Therapeutics Announces Positive Preliminary, Preclinical Data on its Therapeutic for Cutaneous Lupus Erythematosus (CLE), a Chronic Autoimmune Skin Disease

    Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from dermatological indications ranging from atopic dermatitis, psoriasis and acne along with gene therapy treatment for asthmatics, today announced preliminary, preclinical data for its lupus treatment for patients suffering with Cutaneous Lupus Erythematous (CLE), a chronic autoimmune skin disease.

  • PR Newswire

    Hoth Therapeutics, Inc. to Present at 2020 Noble Capital Market's Sixteenth Annual Small-Cap Investor Conference

    Hoth Therapeutics, Inc. (NASDAQ: HOTH) a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from dermatological indications ranging from atopic dermatitis, psoriasis and acne along with gene therapy treatment for asthmatics, today announced that Robb Knie, Chief Executive Officer, will be presenting at the Noble Capital Markets' Sixteenth Annual Investor Conference on February 18, 2020 at the Hard Rock Hotel & Casino, Hollywood, Florida.

  • PR Newswire

    Hoth Initiates Preclinical Gene Therapy Program with NC State for the Treatment of Asthma and Allergic Inflammation

    Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from dermatological indications ranging from atopic dermatitis, psoriasis and acne along with gene therapy treatment for asthmatics, is pleased to announce the initiation of a preclinical study for the treatment of asthma and allergic inflammation in collaboration with North Carolina State University (NC State).

  • PR Newswire

    Hoth Therapeutics to Further its Research of VNLG-152 and Plans Exercise of its Option Agreement with University of Maryland, Baltimore and Isoprene Pharmaceuticals Inc.

    Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company focused on developing new generation therapies for dermatological and immunological disorders such as atopic dermatitis, psoriasis, asthma and acne, announced today that the Company, after further evaluation under its Commercial Evaluation Sublicense and Option Agreement with the University of Maryland, Baltimore (UMB) and Isoprene Pharmaceuticals Inc. will exercise its option for full licensing rights of Dermatology Field to develop and commercialize therapeutic compounds for the treatment of dermatological conditions in humans.

  • PR Newswire

    Hoth Completes Animal Safety Study of Proprietary BioLexa Platform for the Treatment of Atopic Dermatitis

    Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company focused on developing new generation therapies for dermatological and immunological disorders such as atopic dermatitis, psoriasis, asthma and acne, announced today that the Company has concluded its "In-life 28-day animal study" for their BioLexa Platform.

  • GlobeNewswire

    Emerging Markets Report:  A Very Big Deal

    Hoth is well-entrenched in research and development with leading partners in its effort to secure its place in the expanding eczema/atropic dermatitis market. It is also worth noting that eczema is but one in array of opportunities that Hoth is pursuing.

  • PR Newswire

    Hoth Therapeutics Exercises Patent Licensing Option with the George Washington University to Further Develop a Therapeutic for Cancer Patients Suffering Cutaneous Changes Like Rash and Hair Loss, as Well as Other Neurogenic Inflammation Side Effects

    Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from dermatological indications ranging from atopic dermatitis, psoriasis and acne along with gene therapy treatment for asthmatics, announced today it has exercised its option to take an exclusive license for patents owned by the George Washington University (GW). Hoth used the option period to evaluate GW's unique Substance P receptor blocker (Aprepitant) that inhibited cutaneous and other neurogenic inflammation side effects that cancer patients suffer during treatment with anticancer drugs. The exercise of the option agreement allows for Hoth to negotiate an exclusive patent license agreement. The option agreement included pre-negotiated business terms for the exclusive patent license, so Hoth anticipates finalizing the license this month.

  • GlobeNewswire

    Emerging Markets Report: Acne, Eczema, and Asthma

    Since Hoth is intent on developing remedies for these afflictions the size of these markets is important. Hoth announced it was entering into a research collaboration agreement with Weill Cornell Medicine to examine the ability of retinoic acid metabolism blocking agents (RAMBA) to block acne pathogenic gene expression in human keratinocytes, mouse skin, and carcinogenesis in mice. According to Grand View Research, the global acne drug market size is expected to reach USD 5.9 billion by 2025, according to a new report by Grand View Research, Inc., registering a 4.2% CAGR during the forecast period.

  • GlobeNewswire

    Emerging Markets Report: A Pretty Good Month

    Hoth is making news with a lot of new eyes on the story. New investors and prospective investors tuning into Hoth are seeing a company aggressively pursuing partnerships and future market opportunities.

  • PR Newswire

    Hoth Therapeutics, Inc. Issues 2019 Shareholder Letter

    Hoth Therapeutics, Inc. (Nasdaq: HOTH) ("HOTH" or the "Company"), a biopharmaceutical company focused on developing new generation therapies for dermatological and immunological disorders such as atopic dermatitis, psoriasis, asthma and acne, today issued its 2019 Shareholder Letter.

  • PR Newswire

    Hoth Therapeutics Enters into Research Collaboration Agreement with Weill Cornell Medicine to Examine the Efficacy of RAMBA in Blocking Acne Pathogenic Gene Expression

    Hoth Therapeutics, Inc. (Nasdaq: HOTH) ("HOTH" or the "Company"), a biopharmaceutical company focused on developing new generation therapies for dermatological disorders such as atopic dermatitis, chronic wounds, psoriasis and acne, today announced entering into a research collaboration agreement with Weill Cornell Medicine to examine the ability of retinoic acid metabolism blocking agents (RAMBA) to block acne pathogenic gene expression in human keratinocytes, mouse skin, and carcinogenesis in mice.

  • PR Newswire

    Hoth Therapeutics Announces the Appointment of Dr. William Weglicki, M.D. to Scientific Advisory Board

    Hoth Therapeutics, Inc. (NASDAQ: HOTH), ("HOTH" or the "Company"), a biopharmaceutical company focused on developing new generation therapies for dermatological disorders such as atopic dermatitis, chronic wounds, psoriasis and acne, today announced the addition of Dr. William Weglicki, M.D. to the Company's Scientific Advisory Board. While serving on the Board, Dr, Weglicki will oversee Hoth's Aprepitant Program under its Scientific Research Agreement with the George Washington University ("GW").

  • GlobeNewswire

    Emerging Markets Report - Hoth Therapeutics on the Fast Track Toward Delivering Eczema Therapy Products to Market

    Nearly every person suffering from atopic dermatitis, more popularly known as “eczema,” knows just how difficult it can be to find effective remedies for his or her condition. Hoth Therapeutics, Inc. (NASDAQ:HOTH), is one such pharmaceutical company focused on providing eczema patients with a non corticosteriod therapeutic that actually helps treat eczema rather than just stop the itch. Despite the relatively narrow regime of therapies for atopic dermatitis, solutions do abound, and any patient (as with any investor) would wonder what might make one solution better than another.

  • ACCESSWIRE

    Hoth Therapeutics, Inc. to Present at the Investor Summit on December 17th in Philadelphia

    PHILADELPHIA, PA / ACCESSWIRE / December 11, 2019 / Hoth Therapeutics, Inc. (NASDAQ:HOTH), will be presenting at this year's Investor Summit on December 17 th in Philadelphia. The Investor Summit will ...

  • PR Newswire

    Hoth Therapeutics And North Carolina State University Initiate Preclinical Gene Therapy Study For The Treatment Of Asthma

    Hoth Therapeutics, Inc. (Nasdaq: HOTH) ("HOTH" or the "Company"), a biopharmaceutical company focused on developing new generation therapies for dermatological disorders such as atopic dermatitis, chronic wounds, psoriasis and acne, is pleased to announce the initiation of a preclinical study for the treatment of asthma and allergic inflammation in collaboration with North Carolina State University (NC State) beginning on January 1, 2020.

  • PR Newswire

    Hoth Therapeutics and North Carolina State University Enter License Agreement for Gene Therapy

    Hoth Therapeutics, Inc. (Nasdaq: HOTH) ("HOTH" or the "Company"), a biopharmaceutical company focused on developing new generation therapies for dermatological disorders such as atopic dermatitis, chronic wounds, psoriasis and acne, today announced it has entered into a licensing agreement with North Carolina State University (NC State) to study NC State's Exon Skipping Approach for Treating Allergic Diseases.

  • PR Newswire

    Hoth Therapeutics to Attend Benchmark's 8th Annual Discovery 1x1 Conference

    NEW YORK, Nov. 18, 2019 /PRNewswire/ -- Hoth Therapeutics, Inc. (Nasdaq: HOTH) ("HOTH" or the "Company"), a biopharmaceutical company focused on developing new generation therapies for dermatological disorders such as atopic dermatitis, chronic wounds, psoriasis and acne, today announced that its CEO and President, Robb Knie will be attending Benchmark's 8thAnnual Discovery 1x1 Conference. For more information about the conference or to schedule a one-on-one meeting, please contact the conference coordinator. Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders.

  • PR Newswire

    Hoth Therapeutics Initiates Preclinical Study Including Topical Form of Aprepitant for Dermatological Treatment Relating to Side Effects of Cancer Medication

    NEW YORK , Nov. 14, 2019 /PRNewswire/ -- Hoth Therapeutics, Inc. (Nasdaq: HOTH) ("HOTH" or the "Company"), a biopharmaceutical company focused on developing new generation therapies ...

  • We're Not Very Worried About Hoth Therapeutics's (NASDAQ:HOTH) Cash Burn Rate
    Simply Wall St.

    We're Not Very Worried About Hoth Therapeutics's (NASDAQ:HOTH) Cash Burn Rate

    There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

  • PR Newswire

    Hoth Therapeutics Initiates Confirmatory Study for Lupus Treatment

    NEW YORK, Nov. 6, 2019 /PRNewswire/ -- Hoth Therapeutics, Inc. (HOTH) ("HOTH" or the "Company"), a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis–also known as eczema–as well as dermatological and chronic wound disorders, today announced initiating a confirmatory study, related to their proprietary AEA-loaded Z-pods™ in the treatment of Cutaneous Lupus Erythematosus [CLE], a chronic autoimmune disease that affects the skin. The study is being conducted in partnership with Zylö Therapeutics to confirm that topical administration of Hoth's AEA-loaded Z-pods™ inhibits the development of CLE lesions in a well-established animal model of lupus.

  • GlobeNewswire

    Four Innovators Targeting Multi-Billion-Dollar Market Opportunities in: E-Commerce, Healthcare Augmented Reality, and Cannabis

    NEW YORK, Oct. 16, 2019 -- Wall Street Reporter, the trusted name in financial news since 1843, has recently published published CEO Interviews, and conference presentation.

  • PR Newswire

    Hoth Therapeutics to Present at the Dawson James 5th Annual Small Cap Growth Conference

    NEW YORK , Oct. 15, 2019 /PRNewswire/ -- Hoth Therapeutics, Inc. (Nasdaq: HOTH) a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic ...

  • PR Newswire

    Hoth Therapeutics Makes Donation to National Eczema Association in Sponsorship of "National Eczema Awareness Month"

    NEW YORK, Oct. 14, 2019 /PRNewswire/ -- Hoth Therapeutics, Inc. (HOTH) a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis–also known as eczema–as well as dermatological and chronic wound disorders, today announced that the company has made a donation to the National Eczema Association in order to bring continued awareness to National Eczema Awareness Month this October. Atopic dermatitis (AD) is a chronic inflammatory skin disease that presents a significant burden on health-care resources and patients' quality of life.

  • PR Newswire

    Hoth Therapeutics Successfully Completes Phase I of In-Life Dose Escalation Study for Treating Eczema

    NEW YORK, Oct. 8, 2019 /PRNewswire/ -- Hoth Therapeutics, Inc. (HOTH) a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis–also known as eczema–as well as dermatological and chronic wound disorders, today announced that they have completed Phase I of their In-Life dose escalation study. The clinical study was conducted by an independent third party, monitoring the tolerance and toxicity of its proprietary BioLexa Platform on minipigs. "Management is pleased that our BioLexa Platform continues to demonstrate an impressive safety profile during its testing phase," said, Mr. Robb Knie, Chief Executive Officer of Hoth Therapeutics.